Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06978244 | A Study to Assess Safety, Tolerability, and Pharmacokinetics of Ascending Concentrations of Topical Ocular BL1332 in Healthy Volunteers | PHASE1 | ACTIVE NOT_RECRUITING | 24 | — | — | Jul 29, 2025 | Nov 1, 2026 | Jan 27, 2026 | 1 | United States |
To assess the ocular and systemic safety and tolerability of ascending concentrations of topical BL1332 ophthalmic solution eye drops compared with BL1332 vehicle in healthy volunteers, identifying the highest tolerated doses (HTDs)
To assess the ocular and systemic safety and tolerability of ascending concentrations of topical BL1332 ophthalmic solution eye drops compared with BL1332 vehicle in healthy volunteers, identifying the highest tolerated doses (HTDs)
To assess the ocular and systemic safety and tolerability of ascending concentrations of topical BL1332 ophthalmic solution eye drops compared with BL1332 vehicle in healthy volunteers, identifying the highest tolerated doses (HTDs)
To characterize the plasma PK after ocular administration of BL1332 in healthy volunteers
To characterize the plasma PK after ocular administration of BL1332 in healthy volunteers
To characterize the plasma PK after ocular administration of BL1332 in healthy volunteers
To characterize the plasma PK after ocular administration of BL1332 in healthy volunteers
To characterize the plasma PK after ocular administration of BL1332 in healthy volunteers
To characterize the plasma PK after ocular administration of BL1332 in healthy volunteers
To characterize the plasma PK after ocular administration of BL1332 in healthy volunteers
To characterize the plasma PK after ocular administration of BL1332 in healthy volunteers
To characterize the plasma PK after ocular administration of BL1332 in healthy volunteers
| Arm | Type | Description |
|---|---|---|
| BL1332 ophthalmic solution (0.06%, 0.15%, and 0.30% concentrations) | EXPERIMENTAL | BL1332 ophthalmic solution (0.06%, 0.15%, and 0.30% concentrations) administered as topical ocular drops |
| BL1332 vehicle | PLACEBO_COMPARATOR | BL1332 vehicle administered as topical ocular drops |
| Name | Type | Description |
|---|---|---|
| BL1332 ophthalmic solution | DRUG | Both arms taken four times a day for 1 day |
| BL1332 ophthalmic vehicle | DRUG | Both arms taken four times a day for 1 day |
Inclusion Criteria: 1. Written informed consent prior to conduct of any study-related assessment 2. Male and female subjects ≥18 to ≤50 years of age and in good health, as assessed by the Investigator from past medical history, physical examination, and laboratory tests at Screening 3. Vital signs ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 2 | PHASE3 | Bimatoprost, AGN-193408 |
| SpyGlass Pharma, Inc. | SGP | 4 | PHASE3 | Bimatoprost System, Timolol , 0.5% |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 2 | PHASE3 | Test - Bimatoprost 0.01%, Reference - LUMIGAN, Bimatoprost , 0.01%, LUMIGAN 0.01% |
| Glaukos Corp | GKOS | 1 | — | Travoprost |